Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study

Chhatwal, Jagpreet; Samur, Sumeyye; Bethea, Emily; Ayer, Turgay; Kanwal, Fasiha; Hur, Chin; Roberts, Mark S.; Terrault, Norah A.; Chung, Raymond T.

doi:10.1002/hep.29723

Cited by 54 publications

(49 citation statements)

References 46 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The value of this data is even more significant with the growing practice of transplanting HCV‐positive organs into negative donors. These patients are benefited by an expanded donor pool that could decrease wait times on the transplant list . Their transplants would not be possible without DAAs to treat their donor‐derived HCV infections post‐transplantation.…”

Section: Discussionmentioning

confidence: 99%

Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation

Mansour

Hill

Kerr

2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation

Mansour

Hill

Kerr

2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…time that the transplanted organ is exposed to HCV. 23 Further evidence regarding the absolute risk of graft failure with these livers will likely drive this MELD threshold lower. 4,7 Despite the availability of DAA therapy for posttransplant HCV, a positive HCV antibody continues to be a risk factor for organ discard.…”

Section: Re Sultsmentioning

confidence: 99%

Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors

Kwong

Wall

Melcher

et al. 2019

American Journal of Transplantation

112

129

View full text Add to dashboard Cite

| INTRODUC TI ONThe demand for liver transplantation continues to outpace the supply of donor organs in the United States. 1 In the context of this organ shortage, it is essential to make the best use of all transplantable organs. Previously, donor livers infected with hepatitis C virus (HCV) typically have been either discarded or used in patients already infected with HCV. 2-4 Donor livers infected with HCV are still not widely accepted for non-viremic recipients, due to concerns regarding HCV transmission, the natural history of untreated HCV infection after liver transplantation, and limited evidence in this specific population. 5 Highly effective and well-tolerated direct-acting antiviral (DAA) therapies are now available for the treatment of HCV infection and can eliminate HCV in the allograft in greater than 95% of cases. 6In the setting of the ongoing organ shortage, the opioid epidemic, and the advent of DAA therapy, more HCV-infected donor organs are being utilized to expand the donor pool, and non-viremic patients are being given the option to accept these grafts in some centers, including ours. 4,7,8 The aim of our study was to summarize the posttransplant outcomes after donor-derived HCV infection in non-viremic liver transplant recipients at our institution.

show abstract

“…Using a Markov-based simulation model, Chhatwal et al (1) demonstrated that transplanting hepatitis C virus (HCV)-positive livers into HCV-negative recipients can improve waitlist survival. We congratulate Dr. Chhatwal and colleagues on this important contribution.…”

Section: To the Editormentioning

confidence: 99%

Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus–Infected Donors for Uninfected Recipients

et al. 2018

View full text Add to dashboard Cite

Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study

Abstract: Transplanting HCV-positive livers into HCV-negative patients with preemptive DAA therapy could improve patient survival on the LT waiting list. Our analysis can help inform clinical trials and minimize patient harm. (Hepatology 2018;67:2085-2095).

Cited by 54 publications

References 46 publications

Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation

Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation

Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors

Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus–Infected Donors for Uninfected Recipients

Contact Info

Product

Resources

About